Millennium, The Takeda Oncology Company, has initiated a Phase III trial for TAK-700 in patients with advanced prostate cancer. In preclinical studies, TAK-700, a selective, oral, non-steroidal androgen synthesis inhibitor, has been shown to selectively bind to and inhibit the enzyme 17,20 lyase1 in both the testes and adrenal glands. The randomized, double-blind, multi-center, global Phase III study will examine TAK-700 with prednisone compared to placebo with prednisone in patients with che...